Evolus to Report Third Quarter 2023 Results
25 Oktober 2023 - 2:45PM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced that it will report its third quarter 2023 financial
results and provide a business update on Tuesday, November 7, 2023,
after the U.S. financial markets close.
Evolus management will host a conference call and live webcast
to discuss these results at 4:30 p.m. ET that same day. A
question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184
(U.S.) or (201) 389-0877 (international) or connect to the live
webcast via the link on the Investor Relations page of the Evolus
website at www.evolus.com.
Following the completion of the call, a telephonic replay can be
accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415
(international) and using conference number 13741714 An archived
webcast can also be accessed on the Investor Relations page of the
Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram
or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of
Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024325812/en/
Investor Contacts: Idalia
Rodriguez, Ned Mitchell Arbor Advisory Group Email:
ir@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024